SRTS Earnings

SRTS reported its earnings on 2026-02-12, showcasing a revenue of 4.94M against an estimate of 8.35M, resulting in a -40.81% surprise. The EPS was -0.19, surpassing the expected -0.07 by -171.43%. The stock experienced a -16.99% price change on the earnings day and a -15.91% change over the next five days, reflecting market reactions to the results.

Following SRTS's earnings announcement on 2026-02-12, the stock price moved by -16.99% on the day of the release. Over the subsequent five days, it saw a -15.91% change. Historically, SRTS's stock price tends to shift by an average of -1.71% in the 10 days leading up to earnings and 4.82% in the 10 days following, providing insight into potential market.

For 2026/Q1, analysts estimate SRTS's annual revenue to reach 8.23M, while the EPS is projected at -0.05. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between SRTS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, SRTS's stock price typically moves by -1.71% in the 10 days before its earnings and 4.82% in the 10 days after. For the upcoming 2026/Q1 earnings, analysts expect an EPS of -0.05 and revenue of 8.23M.

The company reported disappointing financial results with significant revenue and profit declines, resulting in a net loss. Despite optimistic guidance and international expansion plans, uncertainties like the largest customer's exclusion from projections, unclear FDA approval timelines, and vague management responses during the Q&A raise concerns. Increased expenses and negative EBITDA further contribute to a negative sentiment. Although there is potential in international markets and reimbursement changes, the overall outlook remains negative due to financial underperformance and uncertainties.